Trial data show switching between ABP 654 and reference ustekinumab maintains similar psoriasis control, safety, and ...
FDA expands Tofidence uses, Teva launches Eylea biosimilar in Europe, and Alvotech’s Entyvio rival enters FDA review—boosting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results